Welcome to our dedicated page for Monte Rosa Therapeutics SEC filings (Ticker: GLUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company developing molecular glue degrader (MGD) medicines, Monte Rosa uses SEC reports to describe its clinical programs, collaborations, and financial condition.
Among the most informative documents for GLUE are current reports on Form 8-K, which the company uses to announce material events such as interim clinical data, financial results, and collaboration updates. For example, Monte Rosa has furnished 8-Ks summarizing positive interim Phase 1/2 data for MRT-2359 in metastatic castration-resistant prostate cancer and reporting quarterly financial results and business updates, including progress on MRT-8102, MRT-6160, and its partnerships with Novartis and Roche.
Investors can also reference Monte Rosa’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which the company cites in its forward-looking statements as sources of detailed risk factors and operational information. These periodic filings typically include descriptions of the QuEEN™ discovery engine, the status of key programs such as MRT-8102, MRT-2359, and MRT-6160, and the structure of collaboration and license agreements.
On Stock Titan, GLUE filings are updated in near real time as they appear in the SEC’s EDGAR system. AI-powered tools help summarize lengthy documents, highlight key sections on clinical development, collaboration revenue, and cash runway, and make it easier to locate items on topics such as interim trial results, planned Phase 2 studies, or changes in capital structure. Users can quickly review Form 8-K disclosures about material events alongside the underlying press releases and presentations referenced in those filings.
Monte Rosa Therapeutics, Inc. received an updated ownership report from a group of investment entities associated with Biotechnology Value Fund and Mark N. Lampert. As of December 31, 2025, these Reporting Persons may be deemed to beneficially own a total of 3,835,886 shares of Monte Rosa common stock, representing approximately 5.9% of the 65,117,761 shares outstanding as of October 31, 2025. Individual funds hold portions of this stake, including 2,050,405 shares at Biotechnology Value Fund, 1,496,859 shares at Biotechnology Value Fund II, and 232,097 shares at Biotechnology Value Trading Fund OS. The filing states the shares were not acquired and are not held for the purpose of changing or influencing control of the company.
Baker Bros. Advisors and affiliates report a 6.7% ownership stake in Monte Rosa Therapeutics, Inc. (GLUE) common stock. They beneficially own 4,345,736 shares based on 65,117,761 shares outstanding as of October 31, 2025, as cited from the company’s Form 10-Q.
The stake is held through two investment funds: 667, L.P. with 343,372 shares (0.5% of the class) and Baker Brothers Life Sciences, L.P. with 4,002,364 shares (6.2% of the class). Baker Bros. Advisors LP has discretion over investment and voting decisions, and the filing is certified as being made in the ordinary course of business without intent to influence control.
Monte Rosa Therapeutics, Inc. has filed an automatic shelf registration and a related at-the-market program to sell up to
The company plans to use any net proceeds for general corporate purposes, including research and clinical development of its molecular glue degrader pipeline, working capital, capital expenditures and office expansion. Monte Rosa remains an emerging growth and smaller reporting company with lead programs in immunology, inflammation and oncology.
Monte Rosa Therapeutics, Inc. reported that Edmund Dunn plans to retire from his role as Senior Vice President, Corporate Controller and Principal Accounting Officer, effective April 3, 2026. The company states that his retirement is not due to any disagreement over operations, policies, or practices and that he will not receive severance payments or benefits tied to his departure.
Effective the same date, Matthew Bowen, age 37, will become Corporate Controller and Principal Accounting Officer. Bowen joined Monte Rosa’s finance department after its June 2021 initial public offering and has held roles of increasing responsibility, most recently as Director, Finance. He previously spent seven years in Ernst & Young LLP’s audit and assurance practice, primarily auditing large public companies. The filing notes there are no special arrangements, family relationships, or related-party transactions connected to his promotion.
Monte Rosa Therapeutics, Inc. has a large shareholder group reporting passive ownership of its common stock. Dimension Capital I, L.P. directly holds 5,663,265 shares of common stock, and together with affiliated entities and individuals Adam Goulburn, Zavain Dar, and Nan Li, this position represents 8.7% of the company’s outstanding shares.
The ownership percentage is calculated using 65,117,761 shares of common stock outstanding as of October 31, 2025, as disclosed in Monte Rosa’s Form 10-Q. The reporting group certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Monte Rosa, indicating a passive investment stance rather than an activist position.
Monte Rosa Therapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 11,125,000 shares of common stock at $24.00 per share and pre-funded warrants to purchase 1,375,000 shares at $23.9999 per warrant, with each warrant having a $0.0001 exercise price. The company also granted underwriters a 30-day option to buy up to 1,875,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions.
Monte Rosa estimates net proceeds of approximately $281.6 million from this offering, excluding any proceeds from the underwriters’ option. It plans to use the cash, together with existing balances, to advance MRT-8102 in chronic inflammatory diseases including atherosclerotic cardiovascular disease, further develop its QuEENTM platform across immunology, inflammation and oncology targets, and for working capital and general corporate purposes. The offering is expected to close on or about January 12, 2026, and the company expects its cash and cash equivalents to fund planned operations and capital expenditures into 2029.
Monte Rosa Therapeutics, Inc. is offering 11,125,000 shares of common stock and pre-funded warrants to purchase 1,375,000 shares at $24.00 per share (or $23.9999 per pre-funded warrant). The deal is underwritten, includes a 30‑day option for underwriters to buy up to 1,875,000 additional shares, and is expected to deliver approximately $281.6 million in net proceeds, or about $323.9 million if the option is fully exercised. After this financing, the company expects its cash, cash equivalents and marketable securities to fund operations into 2029.
Management plans to use the cash to advance lead candidate MRT-8102 in chronic inflammatory diseases including ASCVD, and to further develop and deploy its QuEENTM molecular glue degrader discovery platform across immunology, inflammation and oncology targets, as well as for general corporate purposes. The pre-funded warrants have a de minimis $0.0001 exercise price, no expiry, ownership caps between 4.99% and 19.99%, and will not be listed, while investors in this offering will experience immediate and substantial dilution versus net tangible book value.
Versant-affiliated funds reported a lower ownership stake in Monte Rosa Therapeutics, Inc. In Amendment No. 6 to their Schedule 13D, the reporting persons disclose aggregate beneficial ownership of 3,250,069 shares of Common Stock, representing 4.99% of the company’s outstanding shares, based on 65,117,761 shares outstanding as of October 31, 2025. The holdings consist of 2,236,708 shares held by Versant Venture Capital VI, L.P. and 1,013,361 shares held by Versant Vantage I, L.P.
The filing details recent activity, including several open-market sales and pro rata distributions to limited partners. Versant VI sold 15,200 shares at a weighted average price of $14.2503 on November 19, 2025, 10,205 shares at $17.64 on December 16, 2025, and 572,526 shares at a weighted average price of $23.3304 on January 7, 2026. Versant VI also distributed 500,030 shares to its limited partners on December 4, 2025, and Versant Vantage I distributed 560,092 shares on January 8, 2026, both on a pro rata basis without additional consideration.
Monte Rosa Therapeutics, Inc. President & CEO Markus Warmuth reported open-market sales of company common stock on January 7, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025. He sold 3,707 shares at a weighted average price of $23.2422, 1,450 shares at $23.8762, and 309 shares at $24.5736, for a total of 5,466 shares sold.
The filing notes that each weighted average price reflects multiple trades, with sale prices ranging from $22.42 to $24.65. After these transactions, Warmuth beneficially owned 618,937 shares of Monte Rosa common stock in direct ownership.
Monte Rosa Therapeutics filed an amended Form 144 notice covering a planned stock sale. The filing indicates a proposed sale of 5,466 shares of common stock through broker Rockefeller Capital Management on the NASDAQ, with an approximate sale date of January 7, 2026.
The securities to be sold stem from a restricted stock unit (RSU) stock award for 21,865 units, acquired on January 2, 2025 from the issuer as compensation, with the payment date listed as January 2, 2026.
The document also reports that seller Markus Warmuth sold 10,135 Monte Rosa Therapeutics shares on January 5, 2026, generating gross proceeds of $153,759.